Today, the U.S. Food and Drug Administration and the National Institutes of Health (NIH) announced the launch of the Critical Path for Rare Neurodegenerative Diseases (CP-RND)—a public-private partnership aimed at advancing the understanding of neurodegenerative diseases and fostering the development of treatments for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases.
Press Releases
Wednesday, September 14, 2022
Researchers have published two papers describing how they identified a potential new pathway for treating a sporadic form of amyotrophic lateral sclerosis (ALS). The studies were published as part of a cooperative research agreement between the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, and the Switzerland-based biotechnology company GeNeuro Inc.
Tuesday, August 30, 2022
A study funded by the National Institutes of Health found that biomarkers present in the blood on the day of a traumatic brain injury (TBI) can accurately predict a patient’s risk of death or severe disability six months later. Measuring these biomarkers may enable a more accurate assessment of patient prognosis following TBI, according to results published today in Lancet Neurology.
Wednesday, August 10, 2022
Funding supports education of principles of rigorous scientific research
Thursday, August 4, 2022
Today NIH Acting Director Dr. Lawrence Tabak announced the selection of Nina F. Schor, M.D., Ph.D., as the new NIH Acting Deputy Director for Intramural Research (DDIR). She will replace Michael M. Gottesman, M.D., who served as NIH DDIR for the past 29 years.
Thursday, July 14, 2022
A study from the National Institutes of Health describes the immune response triggered by COVID-19 infection that damages the brain’s blood vessels and may lead to short- and long-term neurological symptoms.
Tuesday, July 5, 2022
NIH-funded study identifies brain cells that form boundaries between discrete events.
Monday, March 7, 2022
Researchers from two independent research teams have discovered how the mislocalization of a protein, known as TDP-43, alters the genetic instructions for UNC13A, providing a possible therapeutic target that could also have implications in treating amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other forms of dementia.
Monday, February 28, 2022
Using an experimental drug, researchers were able to suppress a mutated amyotrophic lateral sclerosis (ALS) gene. Studies in mice demonstrate that the therapy could show promise in treating rare, aggressive forms of ALS caused by mutations in the fused in sarcoma (FUS) gene.
Monday, January 24, 2022
Image
Thursday, January 20, 2022